INTS vs IVVD

Intensity Therapeutics, Inc. vs Invivyd, Inc. — Valuation Comparison 2026

INTS

Biological Products, (No Diagnostic Substances)
Intensity Therapeutics, Inc.
Quality
3.7
out of 10
Value Trap
12
SAFE
Price
$4.39
Last close
Models
7/13
Active
VS

IVVD

Biological Products, (No Diagnostic Substances)
Invivyd, Inc.
Quality
4.3
out of 10
Value Trap
24
SAFE
Price
$1.14
Last close
Models
4/13
Active

Model-by-Model Comparison

ModelType INTS Fair ValueINTS Upside IVVD Fair ValueIVVD Upside
Bayesian DCF Intrinsic $3.31 -24.6%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.26 -95.1% $0.02 -98.1%
Dynamic NAV Asset-Based $8.03 +82.9% $0.23 -84.6%
PWERM Option-Based $5.25 +19.6% $0.21 -82.0%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for INTS vs IVVD — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

INTS vs IVVD — Which Stock Is More Undervalued?

IVVD scores higher with a 4.3/10 quality rating vs INTS's 3.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Intensity Therapeutics, Inc. (INTS) and Invivyd, Inc. (IVVD) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

INTS currently trades at $4.39 with a QOC of 3.7/10, while IVVD trades at $1.14 with a QOC of 4.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).